

**FEDERAL RESERVE SYSTEM****Change in Bank Control Notices; Acquisitions of Shares of Banks or Bank Holding Companies**

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. Once the notices have been accepted for processing, they will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than June 2, 1997.

**A. Federal Reserve Bank of Atlanta** (Lois Berthaume, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303-2713:

1. *Ronald Hollis Hyder, and Garry Wayne McNabb*, both of Livingston, Tennessee; to collectively retain, as co-trustees of the Melissa Lynn Oakley 1996 Trust, 27.06 percent of the voting shares of First Holding Company, Inc., Livingston, Tennessee, and thereby indirectly retain First National Bank of the Cumberlands, Livingston, Tennessee.

2. *Leonard P. Mauldin*, Town Creek, Alabama, Macke B. Mauldin, Sheffield, Alabama, and E. Fennel Mauldin, Jr., Sheffield, Alabama, as the MPEFM, II Limited Partnership; to acquire 24.0, 24.5 and 24.6 percent, respectively, for a collectively total of 30.8 percent, of the voting shares of BancIndependent, Inc., Sheffield, Alabama, and thereby indirectly acquire Bank Independent, Sheffield, Alabama.

Board of Governors of the Federal Reserve System, May 13, 1997.

**Jennifer J. Johnson,**

*Deputy Secretary of the Board.*

[FR Doc. 97-12992 Filed 5-16-97; 8:45 am]

BILLING CODE 6210-01-F

(BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than June 12, 1997.

**A. Federal Reserve Bank of Chicago** (Philip Jackson, Applications Officer) 230 South LaSalle Street, Chicago, Illinois 60690-1413:

1. *FBA Bancorp, Inc.*, Chicago, Illinois; to become a bank holding company by acquiring 100 percent of the voting shares of Interim First Bank, S.B., Chicago, Illinois a *de novo* bank, that will acquire First Bank of the Americas, SSB, Chicago, Illinois.

**B. Federal Reserve Bank of St. Louis** (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63102-2034:

1. *Peoples-Marion Bancorp, Inc.*, Marion, Kentucky; to become a bank holding company by acquiring 100 percent of the voting shares of The Peoples Bank, Marion, Kentucky.

In connection with this application, The Peoples Bank Employee Stock Ownership Trust, Marion, Kentucky, also has applied to acquire 47.45 percent of the voting shares of Peoples-Marion, Bancorp, Inc.

**C. Federal Reserve Bank of Dallas** (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. *Fannin Bancorp, Inc., Employee Stock Ownership Plan and Trust*, Windom, Texas; to become a bank holding company by acquiring an additional 0.71 percent, for a total of

25.09 percent, of the voting shares of Fannin Bancorp, Inc., Windom, Texas, and thereby indirectly acquire Fannin Bank, Windom, Texas.

2. *Mansfield Bancshares, Inc.*, Mansfield, Louisiana; to acquire 100 percent of the voting shares of Riverside Bancshares, Inc., Logansport, Louisiana, and thereby indirectly acquire Bank of Logansport, Logansport, Louisiana.

Board of Governors of the Federal Reserve System, May 13, 1997.

**Jennifer J. Johnson,**

*Deputy Secretary of the Board.*

[FR Doc. 97-12993 Filed 5-16-97; 8:45 am]

BILLING CODE 6210-01-F

**FEDERAL RESERVE SYSTEM****Notice of Proposals to Engage in Permissible Nonbanking Activities or to Acquire Companies that are Engaged in Permissible Nonbanking Activities**

The companies listed in this notice have given notice under section 4 of the Bank Holding Company Act (12 U.S.C. 1843) (BHC Act) and Regulation Y, (12 CFR Part 225) to engage *de novo*, or to acquire or control voting securities or assets of a company that engages either directly or through a subsidiary or other company, in a nonbanking activity that is listed in § 225.28 of Regulation Y (12 CFR 225.28) or that the Board has determined by Order to be closely related to banking and permissible for bank holding companies. Unless otherwise noted, these activities will be conducted throughout the United States.

Each notice is available for inspection at the Federal Reserve Bank indicated. Once the notice has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether the proposal complies with the standards of section 4 of the BHC Act.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than June 12, 1997.

**A. Federal Reserve Bank of Atlanta** (Lois Berthaume, Vice President) 104 Marietta Street, N.W., Atlanta, Georgia 30303-2713:

1. *1st United Bancorp*, Boca Raton, Florida; to acquire Seaboard Savings Bank, F.S.B., Stuart, Florida, and thereby engage in operating a savings association, pursuant to § 225.28(b)(4)(ii) of the Board's Regulation Y. The proposed activities will

**FEDERAL RESERVE SYSTEM****Formations of, Acquisitions by, and Mergers of Bank Holding Companies**

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*)

conducted throughout the State of Florida.

Board of Governors of the Federal Reserve System, May 13, 1997.

**Jennifer J. Johnson,**

*Deputy Secretary of the Board.*

[FR Doc. 97-12991 Filed 5-16-97; 8:45 am]

BILLING CODE 6210-01-F

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Administration on Aging**

**Agency Information Collection Activities: Submission for Office of Management and Budget (OMB) Review; Comment Request**

*Title:* Performance (Progress) Reports for Title IV Training, Research, and Discretionary Projects and Programs Grantees

*Description:* Project performance reports provide an understanding of

how projects funded by Title IV of the Older Americans Act are being administered by grantees, in conformance with legislative requirements, pertinent federal regulations, and other applicable instructions and guidelines issued by the Administration on Aging (AoA). This information will be used for federal oversight of the Title IV Training, Research, and Discretionary Projects and Programs.

*Respondents:* Applicants who have been awarded Title IV grants.

*Annual Burden Estimates:*

Instrument	Number of respondents	Average number of responses per respondent	Average burden hours per response	Total burden hours
Performance Report for Title IV Grantees .....	75	2	16	2400

*Additional Information:* Copies of the collection may be obtained by writing to the Administration on Aging, Office of the Executive Secretariat, 330 Independence Avenue, S.W., Washington, DC 20201, Attn.: AoA Reports Clearance Officer.

*OMB Comment:* OMB is required to make a decision, concerning the collection of information, between 30 and 60 days after publication of this document in the **Federal Register**.

Therefore, a comment is best assured of having its full effect if OMB receives it within 60 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, 725 17th Street, N.W., Washington, DC 20503, Attn.: Ms. Wendy Taylor.

Dated: May 8, 1997.

**William F. Benson,**

*Acting Principal Deputy, Assistant Secretary for Aging.*

[FR Doc. 97-10384 Filed 5-16-97; 8:45 am]

BILLING CODE 4150-04-M

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. 97M-0185]

**ELA Medical, Inc.; Premarket Approval of Chorus RM Model 7034 DDDR Pacemaker System and Opus RM Model 4534 SSIR Pacemaker System**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing its approval of the application submitted by ELA Medical, Inc., Plymouth, MN, for premarket approval, under the Federal Food, Drug, and Cosmetic Act (the act), of Chorus RM Model 7034 DDDR Pacemaker System and Opus RM Model 4534 SSIR Pacemaker System. FDA's Center for Devices and Radiological Health (CDRH) notified the applicant, by letter of March 10, 1997, of the approval of the application.

**DATES:** Petitions for administrative review by June 18, 1997.

**ADDRESSES:** Written requests for copies of the summary of safety and effectiveness data and petitions for administrative review to the Dockets Management Branch (HFA-305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.

**FOR FURTHER INFORMATION CONTACT:** Marian Kroen, Center for Devices and Radiological Health (HFZ-450), Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 301-443-8517.

**SUPPLEMENTARY INFORMATION:** On January 18, 1996, ELA Medical, Inc., Plymouth, MN 55441, submitted to CDRH an application for premarket approval of Chorus RM Model 7034 DDDR Pacemaker System and Opus RM Model 4534 SSIR Pacemaker System which includes an IBM compatible microcomputer which has been configured and furnished by ELA Medical, Inc., with CSO 2.46 programming software and is connected to a CPR1 programming lead. These devices are implantable cardiac pacemakers and are indicated for: (1)

Rate adaptive pacing in patients who may benefit from increased pacing rates concurrent with increases in minute ventilation; (2) The generally accepted patient conditions warranting chronic cardiac pacing which include:

- Symptomatic paroxysmal or permanent second or third-degree AV block;
- Symptomatic bilateral bundle branch block;
- Symptomatic paroxysmal or transient sinus node dysfunctions with or without associated AV conduction disorders;
- Bradycardia-tachycardia syndrome to prevent symptomatic bradycardia or some forms of symptomatic tachyarrhythmias; and
- Vaso-vagal syndromes or hypersensitive carotid sinus syndromes.

The Chorus RM is also indicated for dual-chamber and atrial tracking modes in patients who may benefit from maintenance of AV synchrony. Dual-chamber modes are specifically indicated for treatment of conduction disorders that require restoration of both rate and AV synchrony which include:

- Various degrees of AV block to maintain the atrial contribution to cardiac output; and
- VVI intolerance (e.g., pacemaker syndrome) in the presence of persistent sinus rhythm.

In accordance with the provisions of section 515(c)(2) of the act as amended by the Safe Medical Devices Act of 1990, this PMA was not referred to the Circulatory System Devices Panel of the Medical Devices Advisory Committee, an FDA advisory committee, for review and recommendation because the information in the PMA substantially